Global Finasteride Market Size Study & Forecast, by Type (Branded, Generic), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies), by Application (Benign Prostatic Hyperplasia (BPH), Male pattern baldness), an

Global Finasteride Market Size Study & Forecast, by Type (Branded, Generic), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies), by Application (Benign Prostatic Hyperplasia (BPH), Male pattern baldness), and Regional Analysis, 2023-2030

Global Finasteride Market is valued at approximately USD 377.31 million in 2022 and is anticipated to grow with a healthy growth rate of more than 4.2% over the forecast period 2023-2030. Finasteride is a medication that is primarily used to treat benign prostatic hyperplasia (BPH), a disorder that causes men to have an enlarged prostate gland. It is also prescribed for the treatment of male pattern hair loss, a common condition in which men experience hair thinning or hair loss on the scalp. The medication is a sort of 5-alpha-reductase inhibitor, which means that it prevents testosterone from being converted to dihydrotestosterone (DHT), a hormone that causes hair loss and enlargement of the prostate. The rise in prevalence of male pattern baldness, growing awareness about benign prostatic hyperplasia and hair loss, and introduction of novel formulations, coupled with the growing consumer spending on hair care products are the major factors that are fueling the market demand around the world.

In addition, the increasing incidences of Benign Prostatic Hyperplasia (BPH) drive the demand for various medications such as finasteride that are specifically indicated for its treatment. According to Johns Hopkins Medicine, it is estimated that approximately 20% to 30% of men experience BPH symptoms severe enough to require treatment by age 80. Thus, these aforementioned factors are propelling the growth of the Finasteride Market during the estimated period. Moreover, the rising research and development activities, as well as advancements in healthcare infrastructure present various lucrative opportunities over the forecast years. However, the side effects associated with finasteride and availability of alternate medicine are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Finasteride Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing healthcare spending, and surge in investments for the development of finasteride. coupled with the growing awareness about finasteride. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecastyears. The surge in the prevalence of male pattern baldness cases, rise in the number of key players, and increasing aging population are significantly propelling the market demand across the region.

Major market players included in this report are:
Aurobindo Pharma Limited
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd.
Organon & Co.
Cipla Ltd
Intas Pharmaceuticals Ltd.
HETERO LABS LIMITED
Alkem Laboratories Ltd
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.

Recent Developments in the Market:
In January 2023, Happy Head announced the introduction of the company's new SuperCapsulesTM for hair growth, which is developed by top-notch dermatologists and hair restoration specialists. These SuperCapsulesTM are the first of their type as they combine three FDA-approved medications—Finasteride, Minoxidil, and Vitamin D—into a single daily pill.

Global Finasteride Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Type, Distribution Channel, Application, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Branded
Generic

By Distribution Channel:
Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies

By Application:
Benign Prostatic Hyperplasia (BPH)
Male pattern baldness

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa




Companies Mentioned
Aurobindo Pharma Limited
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd.
Organon & Co.
Cipla Ltd
Intas Pharmaceuticals Ltd.
HETERO LABS LIMITED
Alkem Laboratories Ltd
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.